Warrants (Details) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 11 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2021
USD ($)
D
$ / shares
shares
|
Nov. 19, 2020
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Jun. 30, 2022
USD ($)
$ / shares
shares
|
Jun. 30, 2021
USD ($)
|
Mar. 31, 2021 |
Jun. 30, 2022
USD ($)
D
$ / shares
shares
|
Jun. 30, 2021
USD ($)
|
Dec. 02, 2021
USD ($)
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Dec. 31, 2020
USD ($)
shares
|
Dec. 31, 2019 |
|
| Warrants | ||||||||||||
| Gain (loss) from change in fair value of warrant liability | $ | $ 2,074,467 | |||||||||||
| Common Class A [Member] | ||||||||||||
| Warrants | ||||||||||||
| Warrant issued for securities | 10,819,167 | |||||||||||
| P3 Health Partners Inc. | ||||||||||||
| Warrants | ||||||||||||
| Financial Designation, Predecessor and Successor [Fixed List] | Successor | Successor | Successor | Predecessor | Predecessor | Successor | Predecessor | Predecessor | Predecessor | Predecessor | ||
| P3 Health Partners Inc. | Common Class A [Member] | ||||||||||||
| Warrants | ||||||||||||
| Warrants outstanding (shares) | 10,819,167 | 10,819,167 | 10,819,167 | 10,819,167 | 10,819,167 | |||||||
| Warrant issued for securities | 0 | 0 | 0 | |||||||||
| Expected term of warrants | 5 years | 5 years | 5 years | 5 years | 5 years | |||||||
| Exercise price | $ / shares | $ 11.50 | $ 11.50 | $ 11.50 | $ 11.50 | $ 11.50 | |||||||
| Warrants outstanding | $ | $ 11,382,826 | $ 11,382,826 | $ 5,429,009 | $ 5,429,009 | $ 11,382,826 | |||||||
| Gain (loss) from change in fair value of warrant liability | $ | $ 2,271,659 | $ 11,815,093 | $ 1,123,583 | $ 5,953,817 | $ 10,661,579 | $ 7,664,869 | ||||||
| Warrants exercised (in shares) | 0 | 0 | ||||||||||
| Period after completion of business combination warrants become exercisable | 30 days | 30 days | ||||||||||
| Threshold share price | $ / shares | $ 18.00 | $ 18.00 | ||||||||||
| Threshold trading days | D | 20 | 20 | ||||||||||
| Trading period | 30 days | |||||||||||
| Warrant to purchase | 1 | 1 | 1 | 1 | 1 | |||||||
| P3 Health Partners Inc. | Class D Warrants | ||||||||||||
| Warrants | ||||||||||||
| Warrants outstanding (shares) | 0 | 0 | 0 | 0 | 0 | 858,351 | ||||||
| Warrants issued | 858,351 | |||||||||||
| Warrant issued for securities | 858,351 | 858,351 | 858,351 | |||||||||
| Expected term of warrants | 10 years | |||||||||||
| Exercise price | $ / shares | $ 4.68 | $ 4.68 | $ 4.68 | $ 4.68 | ||||||||
| Warrants outstanding | $ | $ 6,316,605 | |||||||||||
| Gain (loss) from change in fair value of warrant liability | $ | $ 0 | |||||||||||
| Warrants exercised (in shares) | 858,351 | |||||||||||
| X | ||||||||||
- Definition The period after specified event in agreement that warrants become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Number of warrants or rights issued. No definition available.
|
| X | ||||||||||
- Definition Threshold Price of the entity's common stock which would be required to be attained to redeem warrants No definition available.
|
| X | ||||||||||
- Definition Threshold number of specified trading days that common stock price must exceed threshold price to trigger redeem feature. No definition available.
|
| X | ||||||||||
- Definition Trading period that common stock price must exceed threshold price to trigger redemption feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Number of warrants exercised during the reported period No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
| X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Indicates designation of financial information when substantially all business or separately identifiable line of business transfers from one entity to another entity. Acceptable values are "Predecessor" and "Successor". Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. No definition available.
|
| X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|